Russian drug market may grow substantially this year

13 June 2023

The Russian drug market grow may substantially this year due to the general stabilization of economic situation in the country and the existing stable demand for drugs from middle and high-priced segments of the market, The Pharma Letter’s local correspondent report.

Most of analysts expect the growth of the market in the second half of the current year although it demonstrated generally negative results at the beginning of the current year.

According to data of the Russian pharma sector analytics agency DSM Group, the total market value in first-quarter 2023 amounted to 663 billion roubles ($8.03 billion), down 12% year-on-year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK